AR107083A1 - ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAME - Google Patents
ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAMEInfo
- Publication number
- AR107083A1 AR107083A1 ARP160103892A ARP160103892A AR107083A1 AR 107083 A1 AR107083 A1 AR 107083A1 AR P160103892 A ARP160103892 A AR P160103892A AR P160103892 A ARP160103892 A AR P160103892A AR 107083 A1 AR107083 A1 AR 107083A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- variable region
- Prior art date
Links
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 title 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
La presente solicitud se refiere a anticuerpos aislados y fragmentos de unión a antígeno de los mismos que se unen selectivamente a CD32b humano. Reivindicación 1: Un anticuerpo aislado o fragmento de unión a antígeno del mismo, que comprende: (a) una región variable de cadena pesada CDR1 que comprende una secuencia de aminoácidos seleccionada de cualquiera de las SEQ ID Nº 1, 4, 7, 53, 56, 59, 105, 108, 111, 157, 160, 163, 209, 212, 215, 261, 264, 267, 313, 316, 319, 365, 368, 371, 417, 420, 423, 469, 472, 475, 521, 524, 527, 547, 550, 553, 573, 576, 579, 625, 628, y 631; (b) una CDR2 de la región variable de cadena pesada que comprende una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID Nº 2, 5, 8, 54, 57, 60, 106, 109, 112, 158, 161, 164, 210, 213, 216, 262, 265, 268, 314, 317, 320, 366, 369, 372, 418, 421; 424, 470, 473, 476, 522, 525, 528, 548, 551, 554, 574, 577, 580, 626, 629, y 632; (c) una CDR3 de la región variable de cadena pesada que comprende una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID Nº 3, 6, 9, 55, 58, 61, 107, 110, 113, 159, 162, 165, 211, 214, 217, 263, 266, 269, 315, 318, 321, 367, 370, 373, 419, 422, 425, 471, 474, 477, 523, 526, 529, 549, 552, 555, 575, 578, 581, 627, 630 y 633; (d) una CDR1 de la región variable de cadena ligera que comprende una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID Nº 14, 17, 20, 66, 69, 72, 118, 121, 124, 170, 173, 176, 222, 225, 228, 274, 277, 280, 326, 329, 332, 378, 381, 384, 430, 433, 436, 482, 485, 488, 534, 537, 540, 560, 563, 566, 586, 589, 592, 638, 641, 644; (e) una CDR2 de la región variable de cadena ligera que comprende una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID Nº 15, 18, 21, 67, 70, 73, 119, 122, 125, 171, 174, 177, 223, 226, 229, 275, 278, 281, 327, 330, 333, 379, 382, 385, 431, 434, 437, 483, 486, 489, 535, 538, 541, 561, 564, 567, 587, 590, 593, 639, 642 y 645; y (f) una CDR3 de la región variable de cadena ligera que comprende una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID Nº 16, 19, 22, 68, 71, 74, 120, 123, 126, 172, 175, 178, 224, 227, 230, 276, 279, 282, 328, 331, 334, 380, 383, 386, 432, 435, 438, 484, 487, 490, 536, 539, 542, 562, 565, 568, 588, 591, 594, 640, 643 y 646; en el que el anticuerpo se une selectivamente a CD32b humana.The present application relates to isolated antibodies and antigen binding fragments thereof that selectively bind human CD32b. Claim 1: An isolated antibody or antigen-binding fragment thereof, comprising: (a) a CDR1 heavy chain variable region comprising an amino acid sequence selected from any of SEQ ID Nos. 1, 4, 7, 53, 56, 59, 105, 108, 111, 157, 160, 163, 209, 212, 215, 261, 264, 267, 313, 316, 319, 365, 368, 371, 417, 420, 423, 469, 472, 475, 521, 524, 527, 547, 550, 553, 573, 576, 579, 625, 628, and 631; (b) a CDR2 of the heavy chain variable region comprising an amino acid sequence selected from any of SEQ ID NO: 2, 5, 8, 54, 57, 60, 106, 109, 112, 158, 161, 164, 210, 213, 216, 262, 265, 268, 314, 317, 320, 366, 369, 372, 418, 421; 424, 470, 473, 476, 522, 525, 528, 548, 551, 554, 574, 577, 580, 626, 629, and 632; (c) a CDR3 of the heavy chain variable region comprising an amino acid sequence selected from any of SEQ ID NO: 3, 6, 9, 55, 58, 61, 107, 110, 113, 159, 162, 165, 211, 214, 217, 263, 266, 269, 315, 318, 321, 367, 370, 373, 419, 422, 425, 471, 474, 477, 523, 526, 529, 549, 552, 555, 575, 578, 581, 627, 630 and 633; (d) a CDR1 of the light chain variable region comprising an amino acid sequence selected from any of SEQ ID NOS 14, 17, 20, 66, 69, 72, 118, 121, 124, 170, 173, 176, 222, 225, 228, 274, 277, 280, 326, 329, 332, 378, 381, 384, 430, 433, 436, 482, 485, 488, 534, 537, 540, 560, 563, 566, 586, 589, 592, 638, 641, 644; (e) a CDR2 of the light chain variable region comprising an amino acid sequence selected from any of SEQ ID NO: 15, 18, 21, 67, 70, 73, 119, 122, 125, 171, 174, 177, 223, 226, 229, 275, 278, 281, 327, 330, 333, 379, 382, 385, 431, 434, 437, 483, 486, 489, 535, 538, 541, 561, 564, 567, 587, 590, 593, 639, 642 and 645; and (f) a CDR3 of the light chain variable region comprising an amino acid sequence selected from any of SEQ ID NOS 16, 19, 22, 68, 71, 74, 120, 123, 126, 172, 175, 178 , 224, 227, 230, 276, 279, 282, 328, 331, 334, 380, 383, 386, 432, 435, 438, 484, 487, 490, 536, 539, 542, 562, 565, 568, 588 , 591, 594, 640, 643 and 646; wherein the antibody selectively binds to human CD32b.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269444P | 2015-12-18 | 2015-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107083A1 true AR107083A1 (en) | 2018-03-21 |
Family
ID=61768601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103892A AR107083A1 (en) | 2015-12-18 | 2016-12-16 | ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAME |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR107083A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110428870A (en) * | 2019-08-08 | 2019-11-08 | 苏州泓迅生物科技股份有限公司 | A kind of method and its application of prediction heavy chain of antibody light chain pairing probability |
-
2016
- 2016-12-16 AR ARP160103892A patent/AR107083A1/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110428870A (en) * | 2019-08-08 | 2019-11-08 | 苏州泓迅生物科技股份有限公司 | A kind of method and its application of prediction heavy chain of antibody light chain pairing probability |
| CN110428870B (en) * | 2019-08-08 | 2023-03-21 | 苏州泓迅生物科技股份有限公司 | Method for predicting antibody heavy chain and light chain pairing probability and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001926A1 (en) | Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017). | |
| PE20190737A1 (en) | ANTI-CD27 ANTIBODIES | |
| CL2020003096A1 (en) | Entpd2 Antibodies, Combination Therapies, and Methods of Using Antibodies and Combination Therapies | |
| CO2018013500A2 (en) | Anti-pd-l1 antibodies and uses thereof | |
| MX2024001803A (en) | ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM. | |
| PE20191208A1 (en) | ANTI-CD73 ANTIBODIES AND USES OF THEM | |
| EA201490053A1 (en) | ANTIBODIES THAT ARE BIND OX40 AND THEIR APPLICATION | |
| PE20171180A1 (en) | ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| AR105267A1 (en) | TAU JOINT ANTIBODIES | |
| AR096617A1 (en) | ANTI-TWEAKR ANTIBODIES AND THEIR USES | |
| AR106991A1 (en) | NEUTRALIZING ANTIBODIES OF THE HUMAN IMMUNODEFICIENCY VIRUS | |
| CO6430469A2 (en) | HUMANIZED ANTIBODIES THAT JOIN CD19 AND ITS USES | |
| MX2017012802A (en) | ANTISORTILINE ANTIBODIES AND METHODS FOR USE. | |
| PE20180499A1 (en) | UNION TO TAU ANTIBODIES | |
| PE20240111A1 (en) | BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF | |
| CO2017004753A2 (en) | Antibodies that bind to ccr6 | |
| ES2776179T3 (en) | Antibodies directed against surface determinants of S. aureus | |
| PE20131403A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM | |
| PE20141908A1 (en) | CD47 ANTIBODIES AND METHODS OF USE THEM | |
| MX366359B (en) | Humanized antibodies against ceacam1. | |
| UY37030A (en) | ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAME | |
| AR109683A1 (en) | ANTIBODIES AGAINST FACTOR XI AND ITS USES | |
| ECSP18084153A (en) | Humanized anti-BASIGIN antibodies and their use | |
| EA202190183A1 (en) | ANTIBODIES TO SIGLEC-5 AND METHODS OF THEIR APPLICATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |